Heiko Schoder

List of Publications by Year
in descending order

166 papers	10,818 citations	34076 52 h-index	33869 99 g-index
175 all docs	175 docs citations	175 times ranked	11864 citing authors

#	Article	IF	Citations
1	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	3.3	4
2	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. Clinical Cancer Research, 2022, 28, 45-56.	3.2	13
3	The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. Journal of Nuclear Medicine, 2022, 63, 1424-1430.	2.8	20
4	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1386-1406.	3.3	24
5	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. Journal of Clinical Oncology, 2022, 40, 1500-1505.	0.8	16
6	PET imaging in renal and bladder cancers. , 2022, , .		0
7	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer. Radiotherapy and Oncology, 2022, 168, 37-39.	0.3	4
8	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	2.8	1
9	Functional imaging using radiomic features in assessment of lymphoma. Methods, 2021, 188, 105-111.	1.9	17
10	Clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in COVID-19 patients with a moderate to high pre-test probability of PE. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 794-799.	3.3	29
11	EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1188-1199.	3.3	23
12	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	3.0	98
13	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2642-2651.	3.3	26
14	Brown adipose tissue is associated with cardiometabolic health. Nature Medicine, 2021, 27, 58-65.	15.2	332
15	Urachal remnant metastasis detected on [68Ga] PSMA-11 PET/CT in an asymptomatic prostate cancer patient with biochemical recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3003-3004.	3.3	1
16	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology, 2021, 23, 1056-1071.	0.6	68
17	Practice and prospects for PET/CT guided interventions. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 20-31.	0.4	9
18	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. Leukemia and Lymphoma, 2021, 62, 2177-2183.	0.6	2

#	Article	IF	Citations
19	Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Diagnostics, 2021, 11, 663.	1.3	16
20	Diagnostic and Prognostic Utility of ¹⁸F-FDG PET/CT in Recurrent Salivary Gland Cancers. American Journal of Roentgenology, 2021, 216, 1344-1356.	1.0	6
21	A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3618-3630.	3.3	21
22	Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3940-3950.	3.3	8
23	A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast Cancer Research and Treatment, 2021, 188, 415-425.	1.1	7
24	Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphomaâ€”a narrative review. Annals of Lymphoma, 2021, 5, 15-15.	4.5	13
25	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 2257-2265.	0.8	32
26	Romidepsin and lenalidomideâ€based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase <scp>I</scp> studies with expansion cohorts. American Journal of Hematology, 2021, 96, 1211-1222.	2.0	16
27	Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 110, 672-679.	0.4	68
28	Brown adipose tissue is associated with healthier body fat distribution and metabolic benefits independent of regional adiposity. Cell Reports Medicine, 2021, 2, 100332.	3.3	51
29	Application of Community Detection Algorithm to Investigate the Correlation between Imaging Biomarkers of Tumor Metabolism, Hypoxia, Cellularity, and Perfusion for Precision Radiotherapy in Head and Neck Squamous Cell Carcinomas. Cancers, 2021, 13, 3908.	1.7	3
30	Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers. Seminars in Nuclear Medicine, 2021, 51, 485-501.	2.5	21
31	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 3109-3117.	0.8	97
32	FDG PET/CT imaging features and clinical utility in COVID-19. Clinical Imaging, 2021, 80, 262-267.	0.8	8
33	Impact of 18F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. European Journal of Cancer, 2021, 159, 60-77.	1.3	6
34	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood, 2021, 138, 2828-2837.	0.6	65
35	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). Blood, 2021, 138, 2447-2447.	0.6	1
36	Metabolic Tumor Volume and Total Lesion Glycolysis Can Predict Response to Very Low Dose Radiotherapy (4 Gy) in Indolent B-Cell Lymphomas. Blood, 2021, 138, 3518-3518.	0.6	1

#	Article	IF	Citations
37	MRI and PET/MRI in hematologic malignancies. Journal of Magnetic Resonance Imaging, 2020, 51, 1325-1335.	1.9	28
38	¹¹C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series. Journal of Nuclear Medicine, 2020, 61, 827-833.	2.8	18
39	18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1446-1457.	3.3	13
40	A pilot study of 13N-ammonia cardiac PET imaging to assess subacute cardiotoxicity following adjuvant intensity-modulated radiotherapy for locally advanced breast cancer. Clinical Imaging, 2020, 68, 283-290.	0.8	8
41	Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncology, The, 2020, 21, e431-e443.	5.1	51
42	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. Radiotherapy and Oncology, 2020, 153, 97-105.	0.3	19
43	Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. Bone Marrow Transplantation, 2020, 55, 2331-2334.	1.3	0
44	Overcoming the COVID-19 Crisis and Planning for the Future. Journal of Nuclear Medicine, 2020, 61, 1096-1101.	2.8	13
45	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 2020, 61, 2442-2447.	0.6	1
46	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood, 2020, 135, 2224-2234.	0.6	62
47	Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging. Nuclear Medicine and Biology, 2020, 84-85, 80-87.	0.3	12
48	Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. Blood Advances, 2020, 4, 1812-1823.	2.5	22
49	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3110-3116.	3.2	36
50	The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. Leukemia and Lymphoma, 2020, 61, 1833-1841.	0.6	9
51	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. Journal of Nuclear Medicine, 2020, 61, 626-629.	2.8	65
52	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Blood, 2020, 136, 17-18.	0.6	5
53	Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. European Journal of Hybrid Imaging, 2020, 4, 16.	0.6	17
54	[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. Cancers, 2020, 12, 1138.	1.7	24

#	Article	IF	Citations
55	Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. Blood, 2020, 136, 50-50.	0.6	0
56	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 2019, 134, 1238-1246.	0.6	86
57	Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2760-2769.	3.3	55
58	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. Cancer, 2019, 125, 2984-2990.	2.0	4
59	Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction. Journal of Nuclear Medicine, 2019, 60, 879-881.	2.8	11
60	Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	3.4	493
61	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of Clinical Oncology, 2019, 37, 1790-1799.	0.8	266
62	An International Survey of PET/CT Clinical Reporting. Journal of Nuclear Medicine, 2019, 60, 478-479.	2.8	1
63	The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians. Journal of Nuclear Medicine, 2019, 60, 1663-1664.	2.8	4
64	¹⁸F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. Journal of Nuclear Medicine, 2019, 60, 335-341.	2.8	123
65	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	7.7	115
66	Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 930-939.	3.3	75
67	Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma. Blood, 2019, 134, 1555-1555.	0.6	4
68	¹¹C-Choline Pharmacokinetics in Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1672-1678.	2.8	11
69	Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features. Radiotherapy and Oncology, 2018, 127, 36-42.	0.3	55
70	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹Zr-Trastuzumab in Patients with Esophagogastric Cancer. Journal of Nuclear Medicine, 2018, 59, 161-166.	2.8	96
71	Positron Emission Tomography/Computed Tomographyâ€"Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217.	3.4	93
72	Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Annals of Surgery, 2018, 267, 898-904.	2.1	9

#	Article	IF	Citations
73	Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. Blood Advances, 2018, 2, 649-655.	2.5	22
74	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood, 2018, 132, 1013-1021.	0.6	90
75	Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement. American Journal of Roentgenology, 2017, 208, 849-853.	1.0	31
76	Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211. Medical Physics, 2017, 44, e1-e42.	1.6	162
77	Multiparametric Imaging of Tumor Hypoxia and Perfusion with¹⁸F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. Journal of Nuclear Medicine, 2017, 58, 1072-1080.	2.8	31
78	Pharmacokinetic Analysis of Dynamic ¹⁸F-Fluoromisonidazole PET Data in Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 911-919.	2.8	22
79	Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics. Physics in Medicine and Biology, 2017, 62, 5327-5343.	1.6	51
80	Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood, 2017, 130, 2196-2203.	0.6	111
81	Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1682-1691.	3.3	33
82	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilageâ€”Case Report. Frontiers in Oncology, 2017, 7, 284.	1.3	7
83	Multimodality imaging using proton magnetic resonance spectroscopic imaging and18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer. World Journal of Radiology, 2017, 9, 134.	0.5	1
84	Teaching Cases in Nuclear Oncology: Head and Neck Cancer. , 2017, , 1569-1583.		0
85	Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer. , 2017, , 507-543.		0
86	Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of Gastrointestinal Oncology, 2016, 7, 506-514.	0.6	12
87	Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. BMC Medical Imaging, 2016, 16, 41.	1.4	122
88	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucoseâ€“Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology, 2016, 34, 2020-2027.	0.8	239
89	Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. Head and Neck, 2016, 38, E1285-93.	0.9	17
90	Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. EJNMMI Research, 2016, 6, 79.	1.1	25

#	Article	IF	Citations
91	Metabolic Tumor Volume in Lymphoma: Hype or Hope?. Journal of Clinical Oncology, 2016, 34, 3591-3594.	0.8	56
92	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood, 2016, 128, 1458-1464.	0.6	61
93	Phase II trial of bevacizumabâ€‰+â€‰cetuximabâ€‰+â€‰cisplatin with concurrent intensityâ€modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E566-70.	0.9	35
94	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirusâ€“Related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 9-17.	0.4	121
95	Novel Approaches to Thyroid Cancer Treatment and Response Assessment. Seminars in Nuclear Medicine, 2016, 46, 109-118.	2.5	30
96	Prospective Study of 3â€²-Deoxy-3â€²-¹⁸F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Journal of Nuclear Medicine, 2016, 57, 728-734.	2.8	41
97	¹⁸F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation. Journal of Nuclear Medicine, 2016, 57, 1052-1057.	2.8	50
98	Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. Journal of Nuclear Medicine, 2016, 57, 334-341.	2.8	16
99	Interim PET Evaluation By Deauville Criteria Is an Effective Risk Stratification Tool in PTCL. Blood, 2016, 128, 186-186.	0.6	3
100	Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance). Blood, 2016, 128, 2953-2953.	0.6	3
101	Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588. Blood, 2016, 128, 4198-4198.	0.6	2
102	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. Blood, 2016, 128, 469-469.	0.6	79
103	Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer. , 2016, , 1-37.		0
104	Teaching Cases in Nuclear Oncology: Head and Neck Cancer. , 2016, , 1-16.		0
105	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. British Journal of Cancer, 2015, 113, 1658-1665.	2.9	15
106	Current Status of the Role of PET Imaging in Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 2015, 52, 138-142.	1.8	15
107	Very low utility of surveillance imaging in earlyâ€stage classic <scp>H</scp>odgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. Cancer, 2015, 121, 1985-1992.	2.0	25
108	Imaging for Staging and Response Assessment in Lymphoma. Radiology, 2015, 276, 323-338.	3.6	139

#	Article	IF	Citations
109	Feasibility of In Situ, High-Resolution Correlation of Tracer Uptake with Histopathology by Quantitative Autoradiography of Biopsy Specimens Obtained Under ¹⁸F-FDG PET/CT Guidance. Journal of Nuclear Medicine, 2015, 56, 538-544.	2.8	28
110	Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. Radiology, 2015, 277, 518-526.	3.6	23
111	A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma. Tumor Microenvironment and Therapy, 2015, 2, 14-18.	1.2	3
112	Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Science Translational Medicine, 2014, 6, 260ra149.	5.8	589
113	Noncontrast Perfusion Single-Photon Emission CT/CT Scanning. Chest, 2014, 145, 1079-1088.	0.4	50
114	Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F]Fluorodeoxyglucose Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1136-1142.	0.4	61
115	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. Oral Oncology, 2014, 50, 802-808.	0.8	34
116	A Prospective Study of 18FDG-PET With CT Coregistration for Radiation Treatment Planning of Lymphomas and Other Hematologic Malignancies. International Journal of Radiation Oncology Biology Physics, 2014, 89, 376-383.	0.4	18
117	Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition. BMJ Case Reports, 2014, 2014, bcr2014206699-bcr2014206699.	0.2	8
118	ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in earlyâ€stage, nonbulky Hodgkin lymphoma. Cancer, 2013, 119, 1203-1209.	2.0	19
119	The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecologic Oncology, 2013, 129, 586-592.	0.6	40
120	To scan or not to scan? The value of radiologic surveillance in early-stage Hodgkin lymphoma. International Journal of Hematologic Oncology, 2013, 2, 181-183.	0.7	0
121	Molecular imaging of prostate cancer. Current Opinion in Urology, 2012, 22, 320-327.	0.9	56
122	¹⁸F-FDG PET/CT Metabolic Tumor Volume and Total Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2012, 53, 1506-1513.	2.8	161
123	Interim [¹⁸F]fluorodeoxyglucose positron emission tomography imaging in stage Iâ€“II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. Leukemia and Lymphoma, 2012, 53, 2143-2150.	0.6	54
124	Normalization of pre-ASCT, FDG-PET imaging with second-line, nonâ€“cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood, 2012, 119, 1665-1670.	0.6	258
125	Target Volume Delineation in Oropharyngeal Cancer: Impact of PET, MRI, and Physical Examination. International Journal of Radiation Oncology Biology Physics, 2012, 83, 220-227.	0.4	60
126	Advances in oncologic imaging. Ca-A Cancer Journal for Clinicians, 2012, 62, 364-393.	157.7	53

#	Article	IF	Citations
127	A prospective evaluation of the utility of 2â€deoxyâ€2â€[¹⁸F]fluoroâ€<scp>D</scp>â€glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer, 2012, 118, 5481-5488.	2.0	122
128	Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer. Molecular Imaging and Biology, 2012, 14, 245-251.	1.3	51
129	Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT. Journal of Nuclear Medicine, 2011, 52, 1727-1732.	2.8	46
130	Reply to A. HÃ¼ttmann et al. Journal of Clinical Oncology, 2010, 28, e490-e491.	0.8	1
131	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2010, 28, 1896-1903.	0.8	293
132	Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer. Clinical Cancer Research, 2010, 16, 6093-6099.	3.2	130
133	Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer. Journal of Clinical Oncology, 2010, 28, 3973-3978.	0.8	165
134	Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 101-108.	0.4	126
135	PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2009, 50, 74S-88S.	2.8	172
136	Hybrid Imaging (SPECT/CT and PET/CT): Improving Therapeutic Decisions. Seminars in Nuclear Medicine, 2009, 39, 308-340.	2.5	118
137	Fundamentals of Molecular Imaging: Rationale and Applications With Relevance for Radiation Oncology. Seminars in Nuclear Medicine, 2008, 38, 119-128.	2.5	25
138	PET Imaging for Response Assessment in Lymphoma: Potential and Limitations. Radiologic Clinics of North America, 2008, 46, 225-241.	0.9	39
139	Clinical Utility of¹⁸F-FDG PET/CT in Assessing the Neck After Concurrent Chemoradiotherapy for Locoregional Advanced Head and Neck Cancer. Journal of Nuclear Medicine, 2008, 49, 532-540.	2.8	247
140	The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Current Opinion in Urology, 2008, 18, 87-97.	0.9	83
141	Advances in positron emission tomography applications for urologic cancers. Current Opinion in Urology, 2008, 18, 65-70.	0.9	33
142	Evaluation of Different Methods of 18F-FDG-PET Target Volume Delineation in the Radiotherapy of Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 439-445.	0.6	38
143	Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma. Blood, 2008, 112, 264-264.	0.6	12
144	Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404. Blood, 2008, 112, 372-372.	0.6	3

#	Article	IF	Citations
145	Deep-Inspiration Breath-Hold PET/CT: Clinical Findings with a New Technique for Detection and Characterization of Thoracic Lesions. Journal of Nuclear Medicine, 2007, 48, 712-719.	2.8	87
146	Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels. Journal of Nuclear Medicine, 2007, 48, 501-507.	2.8	142
147	Screening for cancer with PET and PET/CT: potential and limitations. Journal of Nuclear Medicine, 2007, 48 Suppl 1, 4S-18S.	2.8	49
148	The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2006, 14, 73-81.	0.8	16
149	Molecular targeting of the lymphovascular system for imaging and therapy. Cancer and Metastasis Reviews, 2006, 25, 185-201.	2.7	29
150	Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.. Blood, 2006, 108, 532-532.	0.6	25
151	18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. Journal of Nuclear Medicine, 2006, 47, 755-62.	2.8	183
152	2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 4761-4769.	3.2	210
153	Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2005, 23, 4643-4651.	0.8	462
154	CT in PET/CT: essential features of interpretation. Journal of Nuclear Medicine, 2005, 46, 1249-51.	2.8	27
155	Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET. American Journal of Roentgenology, 2004, 183, 1143-1147.	1.0	54
156	Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion. Radiology, 2004, 231, 65-72.	3.6	372
157	Positron emission imaging of head and neck cancer, including thyroid carcinoma. Seminars in Nuclear Medicine, 2004, 34, 180-197.	2.5	164
158	Positron emission tomography for prostate, bladder, and renal cancer. Seminars in Nuclear Medicine, 2004, 34, 274-292.	2.5	312
159	Positron Emission Tomography/Computerized Tomography Functional Imaging of Esophageal and Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2004, 10, 243-250.	1.0	26
160	PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. Journal of Nuclear Medicine, 2004, 45 Suppl 1, 72S-81S.	2.8	46
161	Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. Journal of Nuclear Medicine, 2004, 45, 559-66.	2.8	60
162	PET/CT: a new imaging technology in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1419-1437.	3.3	133

#	Article	IF	Citations
163	Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. Journal of Nuclear Medicine, 2003, 44, 1789-96.	2.8	235
164	Effect of respiratory gating on quantifying PET images of lung cancer. Journal of Nuclear Medicine, 2002, 43, 876-81.	2.8	253
165	Head, neck, and thyroid. , 0, , 103-127.		0
166	Treatment response and clinical outcomes of well differentiated high grade neuroendocrine tumors to lutetium-177 DOTATATE. Neuroendocrinology, 0, , .	1.2	4